Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 15/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4577327 | 0.91 | NPY5R (0.57) | NPY5RHSD11B1DGAT1AVPR1A | |
| SCHEMBL4577476 | 0.88 | NPY5R (0.55) | NPY5RHSD11B1DGAT1AVPR1A | |
| SCHEMBL6054773 | 0.87 | AVPR1A (0.54) | NPY5RHSD11B1DGAT1AVPR1A | |
| SCHEMBL6054873 | 0.87 | AVPR1A (0.54) | NPY5RHSD11B1DGAT1AVPR1A | |
| SCHEMBL4016619 | 0.85 | NPY5R (0.48) | NPY5RHSD11B1DGAT1SIGMAR1AVPR1A | |
| SCHEMBL6054824 | 0.83 | NPY5R (0.66) | NPY5RHSD11B1DGAT1SIGMAR1AVPR1A | |
| SCHEMBL918154 | 0.78 | NPY5R (1.00) | NPY5R | |
| SCHEMBL5785900 | 0.77 | NPY5R (0.62) | NPY5R | |
| SCHEMBL5433417 | 0.76 | NPY5R (0.48) | NPY5RHSD11B1SIGMAR1 | |
| SCHEMBL4047630 | 0.75 | NPY5R (0.53) | NPY5RDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534074-A4 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1534074-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004009015-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO., INC. (US) | 2004-01-29 | — | — | WO | claimed |
| EP-2906040-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-08-19 | — | — | EP | disclosed |
| EP-2888005-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2887807-A1 | NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2888008-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2888006-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031517-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031515-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031445-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-1534074-A4 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1558252-A4 | SUBSTITUTED FURO 2,3-B| PYRIDINE DERIVATIVES | MERCK & CO INC (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1558252-A2 | SUBSTITUTED FURO 2,3-B] PYRIDINE DERIVATIVES | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1534074-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1492784-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004012671-A2 | SUBSTITUTED FURO [2,3-B] PYRIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004009015-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO., INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003082191-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003063781-A2 | SUBSTITUTED IMIDAZOLES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-08-07 | — | — | WO | disclosed |